Wondering what's happening in today's after-hours session? As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients Lantern Pharma receives FDA clearance to begin Phase 1b/2 trial of LP-184 in advanced NSCLC patients with key mutations and low PD-L1 expression.
EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial Lantern Pharma's LP-184 advances to Phase 1b/2 trial in TNBC after FDA clearance, adding to its Fast Track and Rare Pediatric Disease designations.
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the second quarter of 2024.
LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024 LTRN stock results show that Lantern Pharma missed analyst estimates for earnings per share the first quarter of 2024.
3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire Keep an eye on machine learning stocks. With big demand, we could be looking at a half-trillion-dollar market by 2030.
